Literature DB >> 3599998

Evaluation of long-term results of homograft and heterograft valves in extracardiac conduits.

C Bull, F J Macartney, P Horvath, R Almeida, W Merrill, J Douglas, J F Taylor, M R de Leval, J Stark.   

Abstract

Between 1971 and 1982, 249 patients received right heart extracardiac conduits. The 173 patients who survived 30 days were reviewed retrospectively; 72 had antibiotic-sterilized aortic homografts, 97 had xenografts of various types, and four had valveless tubes. Reoperation for conduit obstruction was required as early as 13 months after the original operation, but actuarial analysis showed no differences in overall performance of homograft and heterograft conduit groups with respect to late death or survival free of conduit obstruction. More important risk factors for late death or the need for reoperation were the severity of the underlying cardiac lesions and the influence of early postoperative complications. When analyzed statistically, the performance of conduits bearing homografts was disappointing, influenced sometimes by complications in the Dacron extension tubes. Repairs dispensing with conduits entirely should be evaluated.

Entities:  

Mesh:

Year:  1987        PMID: 3599998

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Autologous tissue-fragmented extracardiac conduit with rapid, stable endothelialization due to angiogenesis.

Authors:  M Ando; Y Tomizawa; Y Noishiki; M Terada; Y Imai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-03

2.  Results of tricuspid valve replacement for nonrheumatic and noninfective disease.

Authors:  A Renzulli; I Goudevenos; P Santé; S Naik; P R Behl; A Blesovsky
Journal:  Tex Heart Inst J       Date:  1990

3.  Calcification of allograft aortic wall in a rat subdermal model. Pathophysiology and inhibition by Al3+ and aminodiphosphonate preincubations.

Authors:  C L Webb; N M Nguyen; F J Schoen; R J Levy
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.